Compare General Motors Company (GM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Novavax Inc — how do they compare? General Motors Company trades at $76.86 (market cap $70.01B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: General Motors Company is far larger — about 50.4× Novavax Inc's market cap, and General Motors Company pays a 0.93% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| GM | NVAX | |
|---|---|---|
Market Cap | $70.01B | $1.39B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $11.19 |
52-Week Low | $48.89 | $6.22 |
Enterprise Value | $173.34B | $890.94M |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.78, down 0.12% on the day, with a neutral technical signal and strong analyst support (63% buy ratings). Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $3.70 surpassing the $2.61 estimate. Revenue for 2025 was $185.02B, though net income margin narrowed to 1.38%. The company maintains solid cash flow from operations of $26.87B in 2025 and recently announced a $0.18 dividend for H1 2026.
GM presents a value opportunity with low P/S (0.4) and P/B (1.12) ratios, trading below the consensus price target of $102.00. Upside potential is supported by earnings beats and strategic investments in energy and autonomous driving, but risks include margin pressure, rising debt levels (46.79% debt-to-asset in 2024), and competitive auto market dynamics. Institutional sentiment remains bullish despite near-term headwinds.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
